The global alpha emittermarket size reached US$ 1,150.4 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 5,929.6 Million by 2028, exhibiting a growth rate (CAGR) of 28.37% during 2023-2028.
Alpha emitters are substances emitted by radioactive sources that decay after releasing alpha particles. They achieve appropriate biodistribution and associated dose distribution to achieve effective therapy without causing unacceptable acute or long-term side effects. With their exceptionally high cell-killing rates, alpha particles are more destructive to tumor cells than beta particles when used in medical procedures. Consequently, they cause less damage to adjacent normal tissues. Radium, lead and bismuth are some of the radionuclides used in the treatment process. The short range and high linear energy transfer (LET) of alpha particles have made them remarkably appealing to medical research, particularly as a viable treatment method for cancer. There are numerous types of cancer that can be treated with alpha emitters, including ovarian cancer, pancreatic cancer, lymphoma, and melanoma.
Alpha Emitter Market Trends:
The market is majorly driven by extensive and high-end research and development (R&D) activities being conducted in cancer treatment. This can be attributed to the growing awareness regarding the cell-killing abilities of targeted alpha emitters. In line with this, the rising prevalence of various types of cancer among the masses is providing an impetus to the market. Also, the increasing geriatric population that is susceptible to develop numerous cardiac and cancer ailments is creating a positive outlook for the market. Moreover, the rising adoption of targeted anticancer or alpha therapy (TAT) in healthcare facilities is impacting the market positively. The market is further propelled by continual technological advancements and the growing number of new nuclear-medicine-based product approvals. Some of the other factors contributing to the market include rapid urbanization, continual improvements in healthcare infrastructure, rising medical expenditure and inflating disposable income levels of the individuals.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global alpha emittermarket report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type of radionuclide, medical application and end user.
Breakup by Type of Radionuclide:
Breakup by Medical Application:
Breakup by End User:
Medical Research Institutions
Breakup by Region:
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Actinium Pharmaceuticals Inc., Alpha Tau Medical Ltd., Bayer AG, Fusion Pharmaceuticals, IBA RadioPharma Solutions and RadioMedix Inc.
Base Year of the Analysis
Type of Radionuclide, Medical Application, End User, Region
Asia Pacific, Europe, North America, Latin America, Middle East and Africa
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Actinium Pharmaceuticals Inc., Alpha Tau Medical Ltd., Bayer AG, Fusion Pharmaceuticals, IBA RadioPharma Solutions and RadioMedix Inc.
10% Free Customization
Report Price and Purchase Option
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report
The global alpha emitter market was valued at US$ 1,150.4 Million in 2022.
We expect the global alpha emitter market to exhibit a CAGR of 28.37% during 2023-2028.
The rising consumer awareness towards the cell-killing abilities of targeted alpha emitters, along with the increasing number of nuclear medicine-based product approvals, is primarily driving the global alpha emitter market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of various elective cancer treatment procedures to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment, thereby negatively impacting the global market for alpha emitters.
Based on the type of radionuclide, the global alpha emitter market has been segregated into astatine, radium, actinium, lead, bismuth, and others. Among these, radium currently exhibits a clear dominance in the market.
Based on the medical application, the global alpha emitter market can be bifurcated into prostate cancer, bone metastasis, ovarian cancer, pancreatic cancer, endocrine tumors, and others. Currently, ovarian cancer holds the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global alpha emitter market include Actinium Pharmaceuticals Inc., Alpha Tau Medical Ltd., Bayer AG, Fusion Pharmaceuticals, IBA RadioPharma Solutions, and RadioMedix Inc.
Need more help?
Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.